Gonadotropin-releasing hormone analogs in fertility preservation - Lack of biological basis?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 4, Issue 9, 2008, Pages 488-489

  Oktay, Kutluk ^a,b   Sönmezer, Murat ^c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Institute for Fertility Preservation   (United States)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Fertility; Gonadotropin releasing hormone analog; Hodgkin disease; Premature ovarian failure

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FOLLITROPIN RECEPTOR; GONADORELIN DERIVATIVE; PREDNISONE; PROCARBAZINE; SPHINGOSINE 1 PHOSPHATE; VINBLASTINE; VINCRISTINE;

ADULT; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; ELECTRON MICROSCOPY; FEMALE FERTILITY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; NOTE; OVARY CYCLE; OVARY FOLLICLE; OVARY FUNCTION; OVULATION; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; UPREGULATION; XENOGRAFT;

EID: 50049103123     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0892     Document Type: Note

References (7)

1. Blumenfeld Z et al. (2008) Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 89: 166-173
2. Oktay K et al. (2007) Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 12: 1055-1066
3. Oktay K et al. (1997) Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab 82: 3748-3751
4. Familiari G et al. (1993) Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Hum Reprod 8: 2080-2087
5. Waxman JH et al. (1987) Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 19: 159-162
6. Giuseppe L et al. (2007) Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12: 141-147
7. Maltaris T et al. (2007) The effect of a GnRH agonist on cryopreserved human ovarian grafts in severe combined immunodeficient mice. Reproduction 133: 503-509